Clinical Trials Logo

Filter by:
NCT ID: NCT02648204 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

SUSTAIN 7
Start date: January 6, 2016
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

NCT ID: NCT02647866 Completed - Ulcerative Colitis Clinical Trials

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Start date: June 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE) phase for eligible subjects with a clinical response.

NCT ID: NCT02647762 Terminated - Clinical trials for Rheumatoid Arthritis

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Start date: October 30, 2017
Phase: Phase 3
Study type: Interventional

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.

NCT ID: NCT02646865 Completed - Clinical trials for Social Anxiety Disorder

Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety (SCE-CBT)

SCE-CBT
Start date: January 2016
Phase: N/A
Study type: Interventional

This study evaluates the addition of a self-compassion training in the treatment of social anxiety disorder. Half of the participants will receive a self-compassion enhanced group cognitive-behavioral therapy, while the other half will receive standard group cognitive-behavioral therapy.

NCT ID: NCT02641392 Terminated - Crohn's Disease Clinical Trials

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Start date: July 25, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety data of GED-0301 for a period of up to 208 weeks in adult subjects (i.e., ≥ 18 years of age) who participated in the core Phase 3 GED-0301-CD-002 and GED-0301-CD-003 studies and adolescent subjects (i.e., 12 to 17 years of age) who participated in the core Phase 3 GED-0301-CD-003 study. Although all subjects will receive active treatment, this study is double-blinded for the entire 208 weeks for the purpose of preserving the blind of the subject's treatment allocation in the initial, core Phase 3 GED-0301 study. The GED-0301-CD-003 trial was not initiated; see detailed description.

NCT ID: NCT02641015 Completed - Clinical trials for Urinary Tract Infections

Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)

RESCUING
Start date: December 2015
Phase: N/A
Study type: Observational

A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)

NCT ID: NCT02640664 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Rainbow Extension Study

RainbowExt
Start date: June 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)

NCT ID: NCT02639936 Recruiting - Active Tuberculosis Clinical Trials

New Generation IGRA in Immunocompromised Individuals

TBnet#54
Start date: December 2015
Phase: N/A
Study type: Observational

Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients

NCT ID: NCT02638207 Completed - Clinical trials for Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

CIDP
Start date: September 27, 2017
Phase: Phase 3
Study type: Interventional

Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy

NCT ID: NCT02633800 Terminated - Clinical trials for Head and Neck Neoplasms

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Start date: December 22, 2015
Phase: Phase 2
Study type: Interventional

This study will test an investigational study drug called patritumab. It is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance that looks like the experimental product, but is not (placebo). Patritumab may work when combined with other medications that are approved for the treatment of head and neck cancer. They are called cetuximab, cisplatin or carboplatin. All participants will receive the other medications approved for treatment of head and neck cancer, even if they do not receive the experimental product.